Spyre Therapeutics, Inc. - Common Stock (NQ:SYRE)

43.71 +0.50 (+1.16%)

Streaming Delayed Price Updated: 12:07 PM EST, Feb 23, 2026 Add to My Watchlist

Price and Volume

Volume	354,527
Open	43.01
Bid (Size)	43.64 (200)
Ask (Size)	43.76 (300)
Prev. Close	43.21
Today's Range	42.26 - 45.76
52wk Range	10.91 - 43.56
Shares Outstanding	101,192,921
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

From Sizable Stake to Zero: The Likely Reason Why Agios Shares Lost a $94 Million Backer ↗

Today 10:57 EST

Agios Pharmaceuticals develops therapies for rare blood disorders, anchored by its PYRUKYND franchise and early-stage clinical programs.

Via The Motley Fool

Viridian Therapeutics Stock Up 75%, but One Fund Just Sold Off Its $69 Million Stake ↗

Today 10:46 EST

Viridian Therapeutics develops monoclonal antibody therapies targeting rare diseases, with a focus on thyroid eye disease treatments.

Via The Motley Fool

Performance

YTD	+42.9%	+42.9%
1 Month	+36.4%	+36.4%
3 Month	+62.1%	+62.1%
6 Month	+163.6%	+163.6%
1 Year	+105.6%	+105.6%

More News

Spyre Therapeutics Stock Surges This Past Year as $10.5 Million Buy Lifts Stake to $78 Million ↗

Today 10:38 EST

Via The Motley Fool

Biotech Fund Dumps 1.85 Million Centessa Shares as Stock Jumps Over 50% ↗

Today 10:29 EST

Via The Motley Fool

Biotech Fund Dumps $84 Million of Nuvalent With Stock Up 29% ↗

Today 10:21 EST

Via The Motley Fool

Spyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

February 19, 2026

From Spyre Therapeutics, Inc.

Via GlobeNewswire

Spyre Therapeutics Announces Presentations at the 21st ECCO Congress Supporting Differentiated Profile of SPY003 and Novel Animal Studies Demonstrating Superiority of Combination Approach

February 18, 2026

From Spyre Therapeutics, Inc.

Via GlobeNewswire

Spyre Therapeutics Poised for Transformational 2026 With Six Expected Proof-of-Concept Readouts Beginning in Q2

January 12, 2026

From Spyre Therapeutics, Inc.

Via GlobeNewswire

Spyre Therapeutics' CEO Sells 15,000 Shares ↗

January 11, 2026

Via The Motley Fool

Spyre Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

November 04, 2025

From Spyre Therapeutics, Inc.

Via GlobeNewswire

Spyre Therapeutics Announces Positive Interim Phase 1 Results for SPY003, Its Novel, Half-Life Extended anti-IL-23 Antibody

November 04, 2025

From Spyre Therapeutics, Inc.

Via GlobeNewswire

Spyre Therapeutics to Participate in Upcoming November Investor Conferences

October 29, 2025

From Spyre Therapeutics, Inc.

Via GlobeNewswire

Spyre Therapeutics Announces Poster Presentations at American College of Rheumatology (ACR) Convergence 2025

October 24, 2025

From Spyre Therapeutics, Inc.

Via GlobeNewswire

Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $316.2 Million

October 15, 2025

From Spyre Therapeutics, Inc.

Via GlobeNewswire

Domino's Pizza Posts Upbeat Results, Joins Astria Therapeutics, Albertsons Companies, Polaris And Other Big Stocks Moving Higher On Tuesday ↗

October 14, 2025

Via Benzinga

Spyre Therapeutics Announces Pricing of $275.0 Million Public Offering of Common Stock

October 13, 2025

From Spyre Therapeutics, Inc.

Via GlobeNewswire

Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants

October 13, 2025

From Spyre Therapeutics, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Friday's After-Market Session ↗

October 10, 2025

Via Benzinga

Spyre Therapeutics Announces Poster Presentations at United European Gastroenterology Week (UEGW) 2025

October 05, 2025

From Spyre Therapeutics, Inc.

Via GlobeNewswire

This United Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday ↗

September 26, 2025

Via Benzinga

Spyre Therapeutics Doses First Patient in Pioneering Phase 2 SKYWAY Basket Trial of SPY072, the First Anti-TL1A Antibody Studied in Rheumatic Diseases

September 15, 2025

From Spyre Therapeutics, Inc.

Via GlobeNewswire

Spyre (SYRE) Q2 R&D Up 23% Loss Narrows ↗

August 06, 2025

Via The Motley Fool

This Weyerhaeuser Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday ↗

April 08, 2025

Via Benzinga

SPYRE ALERT: Bragar Eagel & Squire, P.C. is Investigating Spyre Therapeutics, Inc. on Behalf of Spyre Stockholders and Encourages Investors to Contact the Firm

December 03, 2024

From Bragar Eagel & Squire

Via GlobeNewswire

SYRE Stock Earnings: Spyre Therapeutics Beats EPS for Q2 2024 ↗

August 07, 2024

Via InvestorPlace

Frequently Asked Questions

Is Spyre Therapeutics, Inc. - Common Stock publicly traded?

Yes, Spyre Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Spyre Therapeutics, Inc. - Common Stock trade on?

Spyre Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Spyre Therapeutics, Inc. - Common Stock?

The ticker symbol for Spyre Therapeutics, Inc. - Common Stock is SYRE on the Nasdaq Stock Market

What is the current price of Spyre Therapeutics, Inc. - Common Stock?

The current price of Spyre Therapeutics, Inc. - Common Stock is 43.71

When was Spyre Therapeutics, Inc. - Common Stock last traded?

The last trade of Spyre Therapeutics, Inc. - Common Stock was at 02/23/26 12:07 PM ET

What is the market capitalization of Spyre Therapeutics, Inc. - Common Stock?

The market capitalization of Spyre Therapeutics, Inc. - Common Stock is 4.42B

How many shares of Spyre Therapeutics, Inc. - Common Stock are outstanding?

Spyre Therapeutics, Inc. - Common Stock has 4B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.